Pfizer’s stock price rose by 0.37% after the company made a major multibillion-dollar deal in its fight against obesity. This move shows that Pfizer is still committed to addressing weight loss, offering investors an affordable entry point into the pharmaceutical industry.
After losing ground with its homegrown obesity pill, Pfizer seemed to be falling behind in the weight-loss market. Patent expirations and declining Covid-19 vaccine sales have reduced growth drivers for the company, leading to a nearly 50% decline in its shares over three years, making it one of the industry’s most affordable big-name companies.
Note: I simplified the text by removing technical jargon (e.g., “PFE 0.37% increase”) and focusing on the main points. I also condensed the article to make it more concise while maintaining the essential information.
Source: https://www.wsj.com/health/pharma/pfizer-stock-obesity-investment-bargain-7cdb6ca2